- IBD
-
Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
-
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
-
Intest Res 2026;24(1):95-102. Published online March 20, 2025
-
DOI: https://doi.org/10.5217/ir.2024.00187
-
-
Abstract
PDF Supplementary Material PubReader ePub
- Background/Aims
Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis. Only a few reports have compared the efficacy and safety of these 2 drugs in real-world practice. We aimed to show our real-world evidence of these drugs and compare the efficacy and safety profiles in the treatment of ulcerative colitis.
Methods This study is a single-center retrospective analysis. Patients treated with tofacitinib or upadacitinib at our hospital between June 2018 and January 2024 who were monitored for 24 weeks were included. The primary outcome was steroid-free clinical remission at 24 weeks. Secondary outcomes were response and remission rates at each time point, time series changes in partial Mayo scores and laboratory results, treatment survival at 24 weeks, and the incidence of adverse events.
Results A total of 68 patients treated with tofacitinib and 34 patients treated with upadacitinib were included. Steroid-free clinical remission rate at 24 weeks was significantly higher in upadacitinib-treated patients than in tofacitinibtreated patients (64.7% vs. 38.2%). The response rates in upadacitinib-treated patients exceeded 60% after 8 weeks of treatment through to 24 weeks, and the rates were higher than those in tofacitinib-treated patients. The incidences of adverse events were 79.4% in upadacitinib-treated patients and 38.2% in tofacitinib-treated patients. The most common adverse event was acne for upadacitinib.
Conclusions Upadacitinib was more effective than tofacitinib in inducing remission in ulcerative colitis patients. The incidence of adverse events was significantly higher with upadacitinib than tofacitinib.
-
Citations
Citations to this article as recorded by 
- Successful treatment of tofacitinib-refractory scleritis associated with multiple systemic inflammatory diseases using upadacitinib
Kodai Yuge, Nobuyo Yawata, Kenichiro Asahara, Satoshi Yamana, Nobuyuki Ono, Koh-Hei Sonoda Immunological Medicine.2026; 49(2): 266. CrossRef - Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
Shintaro Akiyama Intestinal Research.2026; 24(2): 197. CrossRef - Janus Kinase Inhibitors for Inflammatory Bowel Disease: Concise Questions and Answers on Their Use in Clinical Practice
Javier P Gisbert, María Chaparro Inflammatory Bowel Diseases.2026; 32(4): 775. CrossRef - Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha Intestinal Research.2026; 24(1): 27. CrossRef - Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis
Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy Inflammatory Bowel Diseases.2026; 32(9): 1800. CrossRef - Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease
Jeong Hwa Lee, Hae Chang Cho, Jae Myung Cha, Byong Duk Ye, Sung Wook Hwang, Eun Soo Kim Gut and Liver.2026; 20(4): 704. CrossRef - Upadacitinib after tofacitinib in ulcerative colitis
Hyeon Jin Cho, Eun Soo Kim Intestinal Research.2025; 23(3): 229. CrossRef - Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Clara De Francesco, Nunzio Belluardo, Emiliano Giangreco, Maria Cappello, Roberto Ajovalasit, Filippo Mocciaro, Barbara Scrivo, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Con Digestive and Liver Disease.2025; 57(11): 2109. CrossRef - Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs
Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef - Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis
Tareq Alsaleh, Abdul Mohammed, Aimen Farooq, Magda Elamin, Amr Akl, Karim Mohamed Yassin, Ahmed Elnaggar, Jennifer Seminerio Inflammatory Intestinal Diseases.2025; 11(1): 29. CrossRef
-
12,778
View
-
630
Download
-
10
Web of Science
-
10
Crossref
- IBD
-
Early resolution of bowel urgency by budesonide foam enema results in improved quality of life in patients with ulcerative colitis: a multicenter prospective observational study
-
Taku Kobayashi, Kei Moriya, Toshimitsu Fujii, Shigeki Bamba, Shinichiro Shinzaki, Akihiro Yamada, Takashi Hisabe, Shintaro Sagami, Shuji Hibiya, Takahiro Amano, Noritaka Takatsu, Katsutoshi Inagaki, Ken-ichi Iwayama, Toshifumi Hibi
-
Intest Res 2025;23(2):157-169. Published online July 15, 2024
-
DOI: https://doi.org/10.5217/ir.2024.00005
-
-
Abstract
PDF Supplementary Material PubReader ePub
- Background/Aims
Bowel urgency is an important symptom for quality of life determination in patients with ulcerative colitis (UC). Few clinical studies have focused on bowel urgency as an efficacy endpoint. Budesonide foam enema has shown efficacy for clinical and endoscopic improvement in mild-to-moderate UC. We evaluated the improvement of clinical symptoms (bowel urgency), safety, and treatment impact of twice-daily budesonide foam enema on the quality of life in patients with UC.
Methods This open-label, multicenter, prospective observational study comprised a 4-week observation period assessing the effectiveness and safety of twice-daily budesonide foam enema. Mild-to-moderate UC patients who had bowel urgency were included. Patients collected data daily in an electronic patient-reported outcome system or logbooks. The primary endpoint was the rate of resolution of bowel urgency at the end of the 4-week observation period. The rate of bowel incontinence was also assessed.
Results Sixty-one patients were enrolled. Of patients with a final evaluation, the rate of resolution of bowel urgency was 58.5% (31/53; 95% confidence interval, 44.1%–71.9%). Bowel urgency decreased over time, with a significant difference observed on day 7 versus day 0. Bowel incontinence showed a decreasing trend from day 5, with a significant difference confirmed on day 12 versus day 0. The clinical remission rate was 64.4% (38/59; 95% confidence interval, 50.9%–76.4%). One adverse event not related to budesonide rectal foam occurred.
Conclusions The findings suggest that bowel urgency can be improved early with twice-daily budesonide foam enema. No new safety signals were observed.
-
Citations
Citations to this article as recorded by 
- Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis: Insights Into Transmural Inflammation and Symptom Pathophysiology
Kanade Serizawa, Shintaro Sagami, Satoko Umeda, Kunio Asonuma, Moeko Komatsu, Shunsuke Shibui, Masa Maeda, Akira Nogami, Ryo Karashima, Masaru Nakano, Ichiro Maeda, Toshifumi Hibi, Chika Kusano, Taku Kobayashi United European Gastroenterology Journal.2026;[Epub] CrossRef - Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in Japan
Masayuki Saruta, Teppei Omori, Akira Nagaki, Yuki Arai, Minami Umeyama, Shinsuke Kurosu, Kiyotoshi Kuramoto, Yasuo Suzuki Intestinal Research.2026; 24(4): 744. CrossRef - KASID Guidelines for the Medical Treatment of Ulcerative Colitis: 2026
Dong Hyun Kim, Seung Min Hong, Seung Yong Shin, June Hwa Bae, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Myung Ha Kim, Miyoung C The Korean Journal of Gastroenterology.2026; 86(4): 352. CrossRef - The choice of treatment approach for mild and moderate ulcerative colitis: a review
Oleg V. Golovenko, Irina D. Loranskaia, Alexey M. Osadchuk Consilium Medicum.2025; 27(12): 744. CrossRef
-
12,583
View
-
350
Download
-
4
Web of Science
-
4
Crossref
- IBD
-
Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
-
Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto
-
Intest Res 2024;22(3):369-377. Published online July 16, 2024
-
DOI: https://doi.org/10.5217/ir.2023.00194
-
-
Abstract
PDF Supplementary Material PubReader ePub
- Background/Aims
The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles have already been published, reports of long-term real-world data have been limited. We aimed to show our 3-year evidence on the clinical use of tofacitinib for the treatment of UC, focusing on its efficacy and safety profiles.
Methods A retrospective observational study was conducted on patients who started tofacitinib for active refractory UC at our hospital. The primary outcome was the retention rate until 156 weeks after initiating tofacitinib. The secondary outcomes were short-term efficacy at 4, 8, and 12 weeks; long-term efficacy at 52, 104, and 156 weeks; prognostic factors related to the cumulative retention rate; loss of response; and safety profile, including adverse events.
Results Forty-six patients who were able to be monitored for up to 156 weeks after tofacitinib initiation, were enrolled in this study. Continuation of tofacitinib was possible until 156 weeks in 54.3%, with > 50% response rates and > 40% remission rates. Among patients in whom response or remission was achieved and tofacitinib was deescalated after 8 weeks of induction treatment, 54.3% experienced relapse but were successfully rescued by and retained on reinduction treatment, except for 1 patient. No serious AEs were observed in the study.
Conclusions Tofacitinib is effective and safe as long-term treatment in a refractory cohort of UC patients in real-world clinical practice.
-
Citations
Citations to this article as recorded by 
- Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib
Arshdeep Singh, Arshia Bhardwaj, Devanshi Jain, Riya Sharma, Dharmatma Singh, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Manavjot Singh, Pritish Gupta, Tanisha Sehgal, Vandana Midha, Ajit Sood Indian Journal of Gastroenterology.2026; 45(3): 526. CrossRef - Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective
Shintaro Akiyama Intestinal Research.2026; 24(2): 197. CrossRef - Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto Intestinal Research.2026; 24(1): 95. CrossRef - Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team
Seung Min Hong, Dong Hyun Kim, June Hwa Bae, Seung Yong Shin, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Miyoung Choi, Myung Ha Intestinal Research.2026; 24(1): 27. CrossRef - The Evolving Landscape of Advanced Therapies in Inflammatory Bowel Disease: Current Evidence and Emerging Targets
Daniele Balducci, Marta Mosca, Sabrina Monaco, Susanna Faenza, Stefano Fabiani, Fabio Cortellini, Nicola Cesaro, Gianpiero Stefanelli, Salvatore Paba, Maddalena Pecchini, Michele Montori, Marco Valvano Gastrointestinal Disorders.2026; 8(1): 13. CrossRef - Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis
Toshiyuki Sakurai, Masayuki Saruta Internal Medicine.2026;[Epub] CrossRef - Tofacitinib in older patients with ulcerative colitis: balancing efficacy and safety
Yoon Suk Jung Intestinal Research.2026; 24(2): 193. CrossRef - KASID Guidelines for the Medical Treatment of Ulcerative Colitis: 2026
Dong Hyun Kim, Seung Min Hong, Seung Yong Shin, June Hwa Bae, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Seong-Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Myung Ha Kim, Miyoung C The Korean Journal of Gastroenterology.2026; 86(4): 352. CrossRef - In which patients with ulcerative colitis would filgotinib be effective?
Jihye Park Intestinal Research.2025; 23(1): 1. CrossRef - Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety
Rogério Serafim Parra, Renata de Sá Brito Fróes, Daniela Oliveira Magro, Sandro da Costa Ferreira, Munique Kurtz de Mello, Matheus Freitas Cardoso de Azevedo, Aderson Omar Mourão Cintra Damião, Alexandre de Sousa Carlos, Luísa Leite Barros, Maria Luiza Qu BMC Gastroenterology.2025;[Epub] CrossRef - State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review
Yunseok Choi, Suhyun Lee, Hyeon Ji Kim, Taemin Park, Won Gun Kwack, Seungwon Yang, Eun Kyoung Chung Pharmaceuticals.2025; 18(5): 740. CrossRef - Exploring the Factors Associated With the Discontinuation of Tofacitinib in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study
Li‐Huei Chiang, Chia‐Ling Yu, Tzu‐Cheng Tsai, Yao‐Fan Fang International Journal of Rheumatic Diseases.2025;[Epub] CrossRef - Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease
Anja Bizjak, Boris Gole, Gregor Jezernik, Uroš Potočnik, Mario Gorenjak Genes.2025; 16(8): 908. CrossRef - Tofacitinib in acute severe ulcerative colitis: review addressing seven key unmet needs
Chuong Dinh Nguyen, Luan Minh Dang, Thong Duy Vo, Hoang Huu Bui, Eun Soo Kim, Joyce Wing Yan Mak, Choon Jin Ooi Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef - Three Janus kinase inhibitors in ulcerative colitis: is upadacitinib taking the lead?
Yoon Suk Jung Intestinal Research.2025; 23(4): 394. CrossRef - Reevaluating aminosalicylates role in maintaining remission in ulcerative colitis: Systematic review and meta-analysis in the era of biologics
Themba Mudege, Jonathan Soldera World Journal of Meta-Analysis.2025;[Epub] CrossRef - Drug-induced liver injury in inflammatory bowel disease: Challenges in diagnosis and monitoring
Arshdeep Singh, Arshia Bhardwaj, Harmeet Kaur, Ashutosh Bawa, Vandana Midha, Ajit Sood World Journal of Hepatology.2025;[Epub] CrossRef
-
12,362
View
-
243
Download
-
16
Web of Science
-
17
Crossref
- IBD
-
Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
-
Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto
-
Intest Res 2024;22(1):65-74. Published online November 9, 2023
-
DOI: https://doi.org/10.5217/ir.2023.00092
-
-
Abstract
PDF Supplementary Material PubReader ePub
- Background/Aims
Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients including the small bowel, and whether their combined use can improve accuracy.
Methods One hundred and four consecutive patients with ileal and ileocolonic type CD who underwent balloon-assisted enteroscopy (BAE) from October 2021 to August 2022 were enrolled, with clinical and laboratory data prospectively collected and analyzed.
Results Hemoglobin, platelet count, C-reactive protein, leucine-rich alpha-2 glycoprotein (LRG), fecal calprotectin, and fecal hemoglobin all showed significant difference in those with ulcers found on BAE. LRG and fecal calprotectin showed the highest areas under the curve (0.841 and 0.853) for detecting ulcers. LRG showed a sensitivity of 78% and specificity of 80% at a cutoff value of 13 μg/mL, whereas fecal calprotectin showed a sensitivity of 91% and specificity of 67% at a cutoff value of 151 μg/g. Dual positivity for LRG and fecal calprotectin, as well as LRG and fecal hemoglobin, both predicted ulcers with an improved specificity of 92% and 100%. A positive LRG or fecal calprotectin/hemoglobin showed an improved sensitivity of 96% and 91%. Positivity for LRG and either of the fecal biomarkers was associated with increased risk of hospitalization, surgery, and relapse.
Conclusions The biomarkers LRG, fecal calprotectin, and fecal hemoglobin can serve as noninvasive and accurate tools for assessing activity in CD patients confirmed by BAE, especially when used in combination.
-
Citations
Citations to this article as recorded by 
- Leucine-rich alpha-2 glycoprotein reflects transmural inflammation assessed by through-the-scope endoscopic ultrasonography: A prospective study in small-bowel Crohn’s disease
Yuan-Yuan Fang, Min Wang, Meng-Qi Huang, Ling-Yun Li, Cheng-Cheng Tian, Wei Han, Juan Wu, Pei-Pei Zhang, Qiu-Yuan Liu, Qiao Mei, Jing Hu World Journal of Gastroenterology.2027;[Epub] CrossRef - Leucine-rich alpha-2 glycoprotein as a blood biomarker in inflammatory bowel disease: clinical implications and future perspectives
Takayuki Yamamoto Expert Review of Gastroenterology & Hepatology.2026; 20(2): 147. CrossRef - Comparative efficiency of leucine-rich alpha-2 glycoprotein and fecal calprotectin to assess endoscopic activity in Crohn’s disease: a prospective observational study
Tatsuya Kawamura, Takeshi Yamamura, Masanao Nakamura, Keiko Maeda, Tsunaki Sawada, Eri Ishikawa, Kentaro Murate, Takashi Hirose, Takuya Ishikawa, Kazuhiro Furukawa, Takashi Honda, Muneyori Okita, Hiroki Kawashima Inflammatory Bowel Diseases.2026; 32(10): 1969. CrossRef - Clinical utility of magnetic resonance enterography for pediatric Crohn’s disease: a review with illustrative cases and a focus on Japan
Masaki Shimizu, Yoshio Kitazume, Yuko Hayashi, Takashi Ishige, Toshimitsu Fujii Japanese Journal of Radiology.2026;[Epub] CrossRef - Beyond calprotectin: where leucine-rich α2-glycoprotein may fit in small bowel Crohn’s disease monitoring
Tatsuya Kawamura, Takeshi Yamamura, Masanao Nakamura Inflammatory Bowel Diseases.2026; 32(11): 2242. CrossRef - Leucine-rich alpha-2 glycoprotein in combination with C-reactive protein for predicting endoscopic activity in Crohn’s disease: a single-centre, cross-sectional study
Yoshiaki Takada, Hiroki Kiyohara, Yohei Mikami, Masataka Taguri, Ryoya Sakakibara, Yasuhiro Aoki, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Motohiko Kato, Yasushi Annals of Medicine.2025;[Epub] CrossRef - Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba, Osamu Inatomi World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef - The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis
Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Behrad Saeedian, Tannaz Bagheri, Abdulrahman Ismaiel, Satohiro Matsumoto, Nastaran Babajani European Journal of Gastroenterology & Hepatology.2025; 37(8): 891. CrossRef - Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn’s disease activity in the small bowel
Muneyori Okita, Kento Takenaka, Fumihito Hirai, Shinya Ashizuka, Hideki Iijima, Shigeki Bamba, Toshimitsu Fujii, Kenji Watanabe, Yosuke Shimodaira, Hisashi Shiga, Sakiko Hiraoka, Toshihiro Inokuchi, Takeshi Yamamura, Ryo Emoto, Shigeyuki Matsui Journal of Gastroenterology.2025; 60(5): 573. CrossRef - Leucine-rich alpha-2 glycoprotein is useful in predicting clinical relapse in patients with Crohn’s disease during biological remission
Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Sanshiro Kobayashi, Mamiko Aoi, Takashi Tomiyama, Tomomitsu Tahara, Norimasa Fukata, Toshiro Fukui, Makoto Naganuma Intestinal Research.2025; 23(2): 170. CrossRef - Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of three non-invasive markers
Kensuke Takei, Toshihiro Inokuchi, Sakiko Hiraoka, Mikako Ishiguro, Junki Toyosawa, Yuki Aoyama, Shoko Igawa, Keiko Takeuchi, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Seiji Kawano, Toshiharu Mitsuhashi, Motoyuki Otsuka BMC Gastroenterology.2025;[Epub] CrossRef - Usefulness of Prostaglandin E-Major Urinary Metabolite in Monitoring Crohn’s Disease Activity: A Prospective Cross-Sectional Study
Natsuki Ishida, Satoshi Tamura, Tomohiro Takebe, Kenichi Takahashi, Yusuke Asai, Tomoharu Matsuura, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Takanori Yamada, Satoshi Osawa, Ken Sugimoto Inflammatory Bowel Diseases.2025; 31(9): 2420. CrossRef - Which biomarkers best reflect the degree of inflammation in Crohn’s disease?
Jihye Park Intestinal Research.2024; 22(1): 1. CrossRef - Efficacy of serum leucine-rich alpha-2 glycoprotein in predicting findings of Crohn’s disease small bowel lesion in capsule endoscopy
Teppei Omori, Miki Koroku, Shun Murasugi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige Intestinal Research.2024; 22(4): 464. CrossRef - Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kiz Scientific Reports.2024;[Epub] CrossRef
-
10,816
View
-
351
Download
-
15
Web of Science
-
15
Crossref
- IBD
-
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
-
Hiromichi Shimizu, Toshimitsu Fujii, Shuji Hibiya, Maiko Motobayashi, Kohei Suzuki, Kento Takenaka, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe
-
Intest Res 2021;19(1):115-118. Published online June 11, 2020
-
DOI: https://doi.org/10.5217/ir.2020.00030
-
-
PDF Supplementary Material PubReader ePub
-
Citations
Citations to this article as recorded by 
- Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto Intestinal Research.2026; 24(1): 95. CrossRef - Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system
Suqi Zeng, Sihan Zhang, Jianxuan Sun, Junjie Chen Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(9): 14029. CrossRef - Inflammatory bowel disease therapeutics: a bibliometric analysis of tofacitinib research in ulcerative colitis
Jianping Zhou, Yuting Xi, Yaping Zhang, Rui Zhang, Hao Fu, Ce Zhou Frontiers in Pharmacology.2025;[Epub] CrossRef - Association between inflammatory bowel disease, current therapies, and cardiovascular events: a review and meta-analysis of data from 2.2 million individuals
David-Raj Thomas, Gavin Huangfu, Fiona Yeaman, Sara Sukudom, Nick S R Lan, Girish Dwivedi, Lena Thin Journal of Crohn's and Colitis.2025;[Epub] CrossRef - Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease
Anja Bizjak, Boris Gole, Gregor Jezernik, Uroš Potočnik, Mario Gorenjak Genes.2025; 16(8): 908. CrossRef - Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study
Sophie Vieujean, David Laharie, Anthony Buisson, Xavier Roblin, Mathurin Fumery, Stephane Nancey, Pauline Wils, Romain Altwegg, Laurence Seidel, Bénédicte Caron, Laurent Peyrin-Biroulet Digestive and Liver Disease.2024; 56(4): 613. CrossRef - Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
Young-Eun Kim, Ye-Jee Kim, Dae Hyun Jeong, Seonok Kim, Min Jee Kim, Hyeon Hwa Kim, Kyung-Wook Jo, Sang Hyoung Park, Seokchan Hong Seminars in Arthritis and Rheumatism.2024; 65: 152362. CrossRef - Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Axel Dignass, Marla C. Dubinsky, Giovanni Peretto, Paulo G. Kotze, Iris Dotan, Taku Kobayashi, Subrata Ghosh, Fernando Magro, Jose Rocha Faria-Neto, Britta Siegmund, Silvio Danese, Laurent Peyrin-Biroulet Digestive and Liver Disease.2024; 56(8): 1270. CrossRef - Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
Hiromichi Shimizu, Yuko Aonuma, Shuji Hibiya, Ami Kawamoto, Kento Takenaka, Toshimitsu Fujii, Eiko Saito, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto Intestinal Research.2024; 22(3): 369. CrossRef - Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study
Hyuk Yoon, Byong Duk Ye, Sang-Bum Kang, Kang-Moon Lee, Chang Hwan Choi, Joo-young Jo, Juwon Woo, Jae Hee Cheon BMC Gastroenterology.2024;[Epub] CrossRef - Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies
Chien-Hung Lin, Wen-Sheng Liu, Chuan Wan, Hsin-Hui Wang BMJ Open Gastroenterology.2024; 11(1): e001347. CrossRef - Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
María Chaparro, Diana Acosta, Cristina Rodríguez, Francisco Mesonero, Miren Vicuña, Manuel Barreiro-de Acosta, Agnès Fernández-Clotet, Álvaro Hernández Martínez, Maite Arroyo, Isabel Vera, Alexandra Ruiz-Cerulla, Beatriz Sicilia, M. José Cabello Tapia, Ca American Journal of Gastroenterology.2023; 118(7): 1237. CrossRef - Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef - Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, Stephane Zuily, Silvio Danese, Laurent Peyrin‐Biroulet Alimentary Pharmacology & Therapeutics.2023; 57(11): 1231. CrossRef - Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective
Shubhra Mishra, Anuraag Jena, Rinkalben Kakadiya, Vishal Sharma, Vineet Ahuja Expert Review of Gastroenterology & Hepatology.2022; 16(8): 737. CrossRef - Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef - Review article: guide to tofacitinib dosing in patients with ulcerative colitis
Peter M. Irving, Yvette Leung, Marla C. Dubinsky Alimentary Pharmacology & Therapeutics.2022; 56(7): 1131. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Effectiveness and Safety of Tofacitinib for Ulcerative Colitis
Vikas Taneja, Mohammed El-Dallal, Zadid Haq, Kartikeya Tripathi, Hannah K. Systrom, Linda F. Wang, Hyder Said, Paul A. Bain, Youlian Zhou, Joseph D. Feuerstein Journal of Clinical Gastroenterology.2022; 56(10): e323. CrossRef - Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
Laura A. Lucaciu, Nathan Constantine-Cooke, Nikolas Plevris, Spyros Siakavellas, Lauranne A.A.P. Derikx, Gareth-Rhys Jones, Charles W. Lees Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
-
10,544
View
-
268
Download
-
23
Web of Science
-
20
Crossref
-
Real-world data on the effectiveness of risankizumab as induction therapy for ustekinumab-refractory ulcerative colitis
-
Ryo Morikawa, Toshimitsu Fujii, Akiko Tamura, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Kazuo Ohtsuka, Ryuichi Okamoto
-
Received December 30, 2025 Accepted February 19, 2026 Published online August 10, 2026
-
DOI: https://doi.org/10.5217/ir.2025.00338
[Epub ahead of print]
-
-
PDF Supplementary Material PubReader ePub
|